Research & Development: Page 83

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Change Agents

    The Change Agents Not content with the status quo, these individuals have decided to shift the paradigm in their fields and are impacting business processes, technologies, and strategies across the life-sciences industry. Mark Bard Keeping the Focus on Results Education B.S. in health administrat...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Who's on the List -- 2006

    Indexed by Section The Commanders and Chiefs Carol Ammon Diana Anderson, Ph.D. John Benbrook Mark Booth Kurt Brykman Thomas Buckley John J. Campbell William Clapper William Claypool, M.D. Nicholas Colucci William H. Crown, Ph.D. Phil Deschamps Susan Desmond-Hellmann, M.D. Fereydoun Firouz Ginger ...

    By PharmaVoice Team • Jan. 2, 2008
  • clinical trial diversity Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Who's on the List -- 2006

    AbelsonTaylor Jay Carter Advanced Health Media Kevin McMurtry Algorithmic Research Inc. Gadi Aharoni, Ph.D. Ambit Biosciences M. Scott Salka Amgen Inc. Kevin Sharer Amylin Pharmaceuticals Inc. Ginger Graham Archives of Internal Medicine and Archives of Dermatology Patricia Quilty AstraZeneca Barr...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Table of Contents

    The Commanders and Chiefs Steering a company in the right direction is no easy task in today’s highly regulated and competitive environment. These individuals wear the mantle of responsibility well and are the guiding forces of ethics, good corporate citizenship, and strategic vision for their co...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The PharmaVOICE 100 - Letter from the Editor

    What you don’t see in this caricature are the hundreds of moving parts that have to come together to publish this special publication of PharmaVOICE, our second annual issue honoring the 100 most inspiring people in the industry. For all of those parts (and people) I am extraordinarily grateful. ...

    By Taren Grom • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Overcoming the Challenges of Clinical Trials in Community-Based Practices

    AmerisourceBergen Specialty Group Overcoming the Challenges of Clinical Trials in Community-Based Practices Sharon Jameson, RN, BSN, MBA VP, Clinical Research International Oncology Network, an AmerisourceBergen Specialty Group company Clinical trials in community-based practices al...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Marketplace

    Featured Product and Service Showcases AmerisourceBergen Specialty Group Ateb Inc. BioCor Campbell Alliance The Clinical Trial Company Clinlogix Cognos Criterium Inc. D. Anderson & Company Data Communiqué International DVC HealthCare ePharmaceuticals etrials Worldwide Inc. I...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Phase IV Trials -- Improving Product Life After Approval Through Technology

    Phase IV Trials — Improving Product Life After Approval Through Technology John M. Hudak, President and Founder It can be theorized that some of the most important research on pharmaceutical products begins after approval. Increasing the commercial applications of an already approved drug ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Revolutionizing Patient Recruitment: Key Issues and Trends

    Revolutionizing Patient Recruitment Key Issues and Trends Diana L. Anderson, Ph.D., President and CEO Revolutionizing patient recruitment requires a commitment by all stakeholders to challenge the status quo and search for new and innovativ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Global Clinical Trials: Challenge or Opportunity?

    Global Trials June 2006 VIEW on Clinical Services Global Clinical Trials: Challenge or Opportunity? Ed Ikeguchi, M.D., Cofounder and Chief Medical Officer Sponsors are realizing that the ROI of EDC and global clinical trials comes not just from the implementation o...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Patient Retention and the Power of Praise

    Patient Recruitment VIEW on Clinical Services June 2006 Patient Retention and the Power of Praise Anna LeGoff,VP, Patient Retention Liz Moench, President and CEO If overwhelming evidence shows that positive reinforcement can affect worker behavior, what can it do for patients p...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Outsourcing Lessons in Clinical Success

    Outsourcing VIEW on Clinical Services June 2006 BioCor Outsourcing Lessons in Clinical Success Niche CROs with stable project teams can offer operational excellence and strategic input. Lukas Makris, Ph.D., CEO Clinical excellence is a necessary component ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Selecting and Implementing EDC-Enabled CDMS/CTMS -- When

    The E-Arena VIEW on Clinical Services June 2006 Selecting and Implementing EDC-Enabled CDMS/CTMS — When “Should We?” Becomes “How Do We?” Timothy Pratt, Ph.D. Chief Marketing Officer and Principal Scientific Advisor In 2005, between 15% and 20% of all clinical trials in the...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    By Daniel Limbach Letter from the Editor VIEW on Clinical Services June 2006 Any mature industry would be pleased to have a double-digit annual growth trajectory for a year or two. Kalorama analysts predict that during the next five years, the growth of contract drug development will maintain...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Critical Need for Clinical Performance Management

    Clinical-Trial Management June 2006 VIEW on Clinical Services The Critical Need for Clinical Performance Management Bill Stevens Senior Director, Life Science Industry By investing in performance management software, organizations can leverage clinical information ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Table of Contents

    Table of Contents June 2006 VIEW on Clinical Services Letter from the Editor The Forum A Rising Tide For Clinical Services: Contract drug-development expenditures were $19 billion in 2005 and are expected to increase at an annual rate of 17%, eventually exceeding $42 billion by 2010. Company List...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Don't Get Stopped Short by a Shortage of Study Drug - Good Project Management Can Keep Trials Running Smoothly

    Clinical-Trial Managment June 2006 VIEW on Clinical Services Don’t Get Stopped Short by a Shortage of Study Drug – Good Project Management Can Keep Trials Running Smoothly Timothy J. Noffke, VP Life Sciences Managing a clinical trial can be a daunting endeavor, with significant factors...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Streamlining The Investigator-Initiated Trial Program

    Streamlining The Investigator-Initiated Trial Program Nancy Bella, Pharm.D. Integration of an experienced clinical services agency as the driving force of investigator-initiated trials, can bridge the gap between the pharmaceutical company and the investigator,...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Practice Makes Perfect -- E-Clinical Trial Standardization

    The E-Arena June 2006 VIEW on Clinical Services Practice Makes Perfect — E-Clinical Trial Standardization John Cline, CEO By having data in set formats, identifying trends and reporting key pieces of information across multiple trials will be possible. And that’s key ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Improving Efficiency in Clinical Development How to Build and Manage an Environment of Continuous Improvement

    Improving Efficiency in Clinical Development How to Build and Manage an Environment of Continuous Improvement Most clinical leaders deeply understand the need to improve efficiency. The next step is motivating themselves and their organizations to tackle the changes ...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaOutlet

    FDA Draft Guidance Impact on the E-PRO Industry Contributed by Dr. Richard Piazza As some treatment effects are only known to the subject enrolled in a study, patient-reported outcome (PRO) measures have become a common metric in determining treatment efficacy and safety in clinical trials. Advan...

    By Dr. Richard Piazza • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Stepping Up to Challenges Across the Board -- Theresa Kane Musser

    Stepping Up to Challenges Across the Board For every idea and opinion, there are contrary points of view; this give and take is what feeds innovation, propels scientific thinking and discovery, and creates rounded, well-adjusted teams and companies. It’s a perspective that Theresa Kane Musser emb...

    By Kim Ribbink • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    E-Media

    GE Healthcare Launches Laboratory Assets System GE Healthcare has introduced Scientific Asset Services, a laboratory asset services offering that can save pharmaceutical and biotechnology companies up to 20% of their total service costs and optimize service operations. Scientific Asset Services p...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    On the Calendar

    Your Source for Life-Sciences Events and Conference Information Professional education is an ongoing endeavor for most executives. PharmaVOICE has partnerships with every major conference provider serving the life-sciences industry. PharmaVOICE is distributed at more than 150 industry events a ye...

    By PharmaVoice Team • Jan. 2, 2008
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Meeting the Needs of Patients with Rare Diseases

    Incentives designed to bring drugs to the market to treat rare diseases have been successful, yielding 280 products, but there are still many patients without adequate treatment. The National Institutes of Health Office of Rare Diseases (ORD) lists more than 6,000 rare diseases affecting an estim...

    By Cynthia Borda • Jan. 2, 2008